EUVIMEDEUVIMED entdecken
Open Access

A distinct antigen presentation pathway drives potent T cell immunity in lipid nanoparticle–based mRNA vaccines

Ryunosuke Muro iD, Suqi Wang iD, Taku Ito-Kureha iD, Hung Hiep Huynh iD, Kouji Kobiyama iD, Takuya Sugita iD, Kazuo Okamoto iD, Kenta Nakano iD, Tadashi Okamura, Masato Kubo iD, Ken J Ishii iD, Takeshi Nitta iD und 1 weitere

Science Advances · 2026

DOI: 10.1126/sciadv.aec7827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Ryunosuke Muro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Antigen Presentation, RNA, Messenger, CD8-Positive T-Lymphocytes, Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Takeda Science Foundation, Nakatomi Foundation, Uehara Memorial Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid nanoparticle–encapsulated mRNA (mRNA-LNP) vaccines trigger the potent differentiation of antigen-specific cytotoxic CD8 T cells in addition to antibody production. Despite its high immunogenicity, the cellular mechanisms by which mRNA-LNP induces such unusual immune responses remain largely unclear. Here, we show that mRNA-LNP induces potent and long-lasting CD8 T cell expansion through an antigen presentation mechanism that differs from that of conventional adjuvants. In mice immunized with mRNA-LNP, the number of antigen-specific CD8 T cells was one order of magnitude higher than that induced by combining antigen proteins with immunostimulants such as lipopolysaccharide or polyinosinic:polycytidinic acid. Intramuscularly administered mRNA-LNPs were mainly taken up by migratory type 2 conventional dendritic cells in draining lymph nodes, resulting in notably strong and persistent antigen presentation through major histocompatibility complex class I. Furthermore, CD8 T cell induction by mRNA-LNP required migratory dendritic cells but not the traditional cross-presentation pathway that is otherwise essential for antiviral and antitumor immunity. Thus, the mRNA-LNP formulation exerts unconventional immune responses through a different antigen-presentation pathway from conventional component vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigen PresentationRNA, MessengerCD8-Positive T-LymphocytesNanoparticlesmRNA VaccinesLipidsAnimalsMiceDendritic CellsNanovaccinesFemaleHistocompatibility Antigens Class ILiposomes

Substanzen

RNA, MessengerLipid NanoparticlesmRNA VaccinesNanovaccinesLipidsHistocompatibility Antigens Class ILiposomes

Autor:innen und Institutionen

  • Department of Immunology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
  • Division of Molecular Pathology, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
  • Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Division of Rheumatology, Department of Medicine, University of California San Diego, La Jolla, CA, United States.
  • Division of Immune Environment Dynamics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

ORCID-Profile: Ryunosuke Muro, Suqi Wang, Taku Ito-Kureha, Hung Hiep Huynh, Kouji Kobiyama, Takuya Sugita, Kazuo Okamoto, Kenta Nakano, Masato Kubo, Ken J Ishii, Takeshi Nitta, Hiroshi Takayanagi

Förderung

  • Takeda Science Foundation
  • Nakatomi Foundation
  • Uehara Memorial Foundation
  • Japan Agency for Medical Research and Development
  • Cancer Research Institute, Kanazawa University
  • Japan Society for the Promotion of Science
  • UTOPIA Young Researcher Development Program
  • Astellas Foundation for Research on Metabolic Disorders

Zitieren

APA

Muro, R., Wang, S., Ito-Kureha, T., Huynh, H. H., Kobiyama, K., Sugita, T., Okamoto, K., Nakano, K., Okamura, T., Kubo, M., Ishii, K. J., Nitta, T., & Takayanagi, H. (2026). A distinct antigen presentation pathway drives potent T cell immunity in lipid nanoparticle–based mRNA vaccines. Science Advances. https://doi.org/10.1126/sciadv.aec7827

Vancouver

Muro R, Wang S, Ito-Kureha T, Huynh HH, Kobiyama K, Sugita T, et al. A distinct antigen presentation pathway drives potent T cell immunity in lipid nanoparticle–based mRNA vaccines. Science Advances. 2026. doi:10.1126/sciadv.aec7827

BibTeX
@article{Muro2026,
  author = {Muro, Ryunosuke and Wang, Suqi and Ito-Kureha, Taku and Huynh, Hung Hiep and Kobiyama, Kouji and Sugita, Takuya and Okamoto, Kazuo and Nakano, Kenta and Okamura, Tadashi and Kubo, Masato and Ishii, Ken J and Nitta, Takeshi and Takayanagi, Hiroshi},
  title = {A distinct antigen presentation pathway drives potent T cell immunity in lipid nanoparticle–based mRNA vaccines},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aec7827}
}
Kostenlos starten →